Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide

Elie G. Dib, Emmanuel Antonarakis, Matthew J. Wasco, Steven F. Powell

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
JournalClinical Genitourinary Cancer
StateAccepted/In press - Jan 1 2018


  • CDK12
  • Checkpoint inhibitor
  • Homologous recombination
  • Mismatch-repair deficiency
  • PDL-1

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this